
Reprogramming Immunity. Reshaping Possibility.
noma is advancing a new class of small-molecule therapies that restore immune function in cancer and autoimmune disease. Our science is rooted in immunology and translational oncology, with a focus on reactivating suppressed immune pathways and targeting overlooked drivers of disease progression.

Restoring the Immune System’s Potential
-
Despite major advances in immunotherapy, many patients with aggressive or late-stage cancers still face poor outcomes. Standard treatments like chemotherapy and radiation can damage the immune system, especially innate immune cells like natural killer (NK) cells, which are essential for early tumor control. Tumors also create highly suppressive environments that disable immune activity, particularly in the tumor microenvironment (TME), leading to therapy resistance and relapse.
-
At noma, we target the overlooked mechanisms that tumors use to evade immune detection. Our focus is on restoring NK cell function, which plays a central role in the body's first line of defense against cancer. NK cells don’t require prior sensitization to attack, and they help recruit other immune cells like dendritic cells and T cells. By reversing immune dysfunction and reactivating NK cell responses within the TME, we aim to deliver more durable outcomes with fewer off-target effects.
-
Our small molecules are designed to reinvigorate NK cell cytotoxicity and reprogram the immune environment in favor of tumor rejection. These therapies not only help eliminate immune-evasive tumors but also facilitate the formation of long-term immune memory through better cross-talk between NK cells and the adaptive immune system. With strong preclinical data, our approach represents a next-generation immunotherapy platform rooted in innate immune modulation.

Meet the Team
noma therapeutics was founded by scientists from Harvard Medical School and Kentucky College of Medicine with deep experience in immunology, oncology, and translational research. Together, we are committed to developing first-in-class therapies that restore immune function and reshape cancer treatment from the ground up.
-
Co-founderDr. Yang is a professor of cancer biology whose research explores tumor progression, drug resistance, and cancer immunotherapy. His work on NAC1 and metabolic reprogramming has uncovered novel therapeutic strategies that directly inform NOMA’s scientific direction.
-
Co-founderChrispus is a postdoctoral fellow in immunology with a focus on innate immune regulation and NK cell biology. His research has led to multiple discoveries in immune evasion and novel therapeutic targets, forming the scientific backbone of noma’s approach.
-
Co-founderThomas is a biomedical engineer and research associate at Harvard Medical School, where he has spent the past two years studying cytokine signaling, immune modulation, and tumor microenvironment dynamics in cancer. He leads strategy and translational development at noma.
Follow Us On Social
Follow Us On Social
Contact Us
Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!